Identifying complications of cancer treatments early on can be vital. We are making the process simple.


 Our innovative device helps to rapidly identify chemotherapy patients who are at risk of a life threatening complication called neutropenic sepsis.

Neutropenic sepsis prematurely takes tens of thousands of lives each year and costs healthcare systems tens of billions of dollars.

Through better triaging, Neutrocheck has the potential to save thousands of lives, free up valuable healthcare resources, and make patients'

lives easier, simpler, and better.


cancer care.


A growing vision.

Neutrocheck wins SBRI Award 

Neutrocheck has been granted a Small Business Research Initiative (SBRI) award. The awards are designed to "enable the NHS to access innovations that solve unmet needs", and will provide support to fast-track our technology through the next stages of commercialisation.


Harvard President's Innovation Challenge Semi-Finalists

Neutrocheck has been accepted as a member of  Harvard Innovation Labs and selected as a semi-finalist of the President's Innovation Challenge. We look forward to the next steps of the competition!

We are in this together.

Our multi-disciplinary team ensures we are in the best position to successfully address patient need, while empowering patients and healthcare professionals, improving safety and delivering results.